Compare CVI & APLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CVI | APLS |
|---|---|---|
| Founded | 1906 | 2009 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 2.7B |
| IPO Year | 2006 | 2015 |
| Metric | CVI | APLS |
|---|---|---|
| Price | $21.10 | $22.25 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 3 | 20 |
| Target Price | $26.67 | ★ $32.16 |
| AVG Volume (30 Days) | 1.1M | ★ 2.3M |
| Earning Date | 05-20-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 350.00 | 64.04 |
| EPS | 0.27 | ★ 0.65 |
| Revenue | ★ $7,162,000,000.00 | $781,367,000.00 |
| Revenue This Year | N/A | $31.31 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $83.37 | ★ $34.22 |
| Revenue Growth | N/A | ★ 97.02 |
| 52 Week Low | $15.10 | $16.10 |
| 52 Week High | $41.67 | $30.48 |
| Indicator | CVI | APLS |
|---|---|---|
| Relative Strength Index (RSI) | 35.04 | 47.24 |
| Support Level | $22.60 | $21.30 |
| Resistance Level | $23.63 | $22.41 |
| Average True Range (ATR) | 1.08 | 1.05 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 32.71 | 32.86 |
CVR Energy Inc is a holding company that engages in petroleum refining and nitrogen fertilizer manufacturing through its subsidiaries. Subsidiaries include several complex, full-coking crude oil refineries, along with a crude oil gathering system, pipelines and storage tanks, and marketing and supply. The company's refineries can process blends of a variety of crude oil ranging from heavy sour to light sweet crude oil. Crude oil for CVR's refineries is supplied through its wholly-owned gathering system and pipeline. From its refineries, CVR supplies products through tanker trucks directly to customers located in close geographic proximity and customers at throughput terminals. The company's customers include retailers, railroads, and farm cooperatives.
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.